Signaling of IL-4 and IL-13, two of
the key drivers of
type 2
inflammation, plays an important
role in PN

The distinct and overlapping roles of IL-4 and IL-133-10

Increased IL-4 and IL-13 signaling directly enhances stimulation of sensory neurons and also leads to
dysregulation of the immune system and skin, resulting in the itch-scratch cycle and the formation of nodules

a Including Th2, Th17, and Th22 cells, eosinophils, and basophils.

The unique role of IL-4 IN TYPE 2 INFLAMMATION

IL-4 is an orchestrator of Th2
response, creating a positive
feedback
loop that leads to dysregulated
secretion of IL-4,
IL-13, and IL-3111,b

b Type 2 cytokines (eg, IL-4/IL-13/IL-31) may also be
produced by other immune cells, such as ILC2.12

il4-inflamation

b Type 2 cytokines (eg, IL-4/IL-13/IL-31) may also be
produced by other immune cells, such as ILC2.12

DUPIXENT is the only dual inhibitor of IL-4 and IL-13 signaling1,2

 

INHIBITION OF IL-4 AND IL-13
SIGNALING HAS A SUBSTANTIAL
IMPACT ON DISEASE

HELPS REDUCE TYPE 2
INFLAMMATION1,3,5,6,10

HELPS REDUCE
ITCH4,13-16

HELPS ACHIEVE
NODULE CLEARANCE1,7-9

  • Helps break itch-scratch cycle
  • May reduce nerve sensitization
+
  • May reduce skin fibrosis

The mechanism of dupilumab action has not been definitively established.

c Dimerization is when 2 protein subunits combine to form a larger complex. IL-4 and IL-13 signaling requires dimerization of IL-4Rα with either the common gamma chain (for IL-4 signaling) or IL-13R (for IL-13 or IL-4 signaling).

Identifying DUPIXENT Patients
Consider whether your patient with prurigo nodularis may be a candidate
for DUPIXENT. Take a look at our patient profiles.
Identify Patients